Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 6Recruiting 2Terminated 1

Sponsor Class

OTHER 6INDUSTRY 6

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Genitourinary 6

Conditions

Neoplasms 1905Breast Neoplasms 1426Carcinoma, Non-Small-Cell Lung 1179Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 624Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Recurrence 374Lymphoma 374Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

radium Ra 223 dichloride 1enzalutamide 1dactolisib 1VT-464 1NVP-BKM120 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Castration-resistant Prostate Cancer × Clear all
NCT02669771 2024-11-21

Long-Term Specified Drug Use-Results Survey for Xtandi Capsule

Astellas Pharma Inc

Completed
1,018 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT04232761 2024-07-17

RAPIT

Bayer

Completed
194 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT04962880 2023-04-14

PROSPECT

AstraZeneca

Completed
388 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT03136640 2021-10-19

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Modra Pharmaceuticals

Phase 1 Completed
23 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis

Phase 1 Completed
43 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02361086 2019-02-01

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Innocrin Pharmaceutical

Phase 1/2 Completed
21 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡